Characterization of a reduced peptide bond analogue of a promiscuous CD4 T cell epitope derived from the Plasmodium falciparum malaria vaccine candidate merozoite surface protein 1

Molecular Immunology

Volumn 41, Issue 8, 2004, Pages 775-784

  Bastian, Max ^a   Lozano, José Manuel ^b   Patarroyo, Manuel Elkin ^b   Pluschke, Gerd ^a   Daubenberger, Claudia A ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b Carrera 50 No 26 00   (United States)

Author keywords

Antigenicity and immunogenicity; Human T cell clones; Merozoite surface protein 1; Pseudo peptides; Single D amino acid replacement analogues Plasmodium falciparum

Indexed keywords

CD4 ANTIGEN; DEXTRO AMINO ACID; EPITOPE; HLA ANTIGEN CLASS 2; LEUCINE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MONOCLONAL ANTIBODY; TRYPSIN; VALINE;

ALLELE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVITY; CELL STIMULATION; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; MONKEY; NONHUMAN; OUTBRED STRAIN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; T LYMPHOCYTE; VACCINATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES; HLA-DP ANTIGENS; HLA-DR ANTIGENS; HUMANS; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; PEPTIDES; PLASMODIUM FALCIPARUM;

PLASMODIUM FALCIPARUM;

EID: 3242727586     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2004.04.019     Document Type: Article

References (42)

1. Albo F., Cavazza A., Giardina B., Lippa S., Marini M., Roda L.G., Spagnoli G. Degradation of the immunogenic peptide gp100 (280-288) by the monocyte-like U937 cell line. Peptides. 24:2003;371-378
2. Benkirane N., Friede M., Guichard G., Briand J.P., Van Regenmortel M.H., Muller S. Antigenicity and immunogenicity of modified synthetic peptides containing D-amino acid residues. J. Biol. Chem. 35:1993;26279-26285
3. Bianco A., Zabel C., Walden P., Jung G. N-hydroxy-amide analogues of MHC-class I peptide ligands with nanomolar binding affinities. J. Pept. Sci. 4:1998;471-478
4. Calbo S., Guichard G., Muller S., Kourilsky P., Briand J.P., Abastado J.P. Antitumor vaccination using a major histocompatibility complex (MHC) class I-restricted pseudopeptide with reduced peptide bond. J. Immunother. 23:2000;125-130
5. Carvalho L.J., Daniel-Ribeiro C.T., Goto H. Malaria vaccine: candidate antigens, mechanisms, constraints and prospects. Scand. J. Immunol. 56:2002;327-343
6. Cheung A., Leban J., Shaw A.R., Merkli B., Stocker J., Chizzolini C., Sander C., Perrin L.H. Immunization with synthetic peptides of a Plasmodium falciparum surface antigen induces antimerozoite antibodies. Proc. Natl. Acad. Sci. USA. 83:1986;8328-8332
7. Cotton J., Herve M., Pouvelle S., Maillere B., Menez A. Pseudopeptide ligands for MHC II-restricted T cells. Int. Immunol. 10:1998;159-166
8. Cubillos M., Espejo F., Purmova J., Martinez J.C., Patarroyo M.E. Alpha helix shortening in 1522 MSP-1 conserved peptide analogues is associated with immunogenicity and protection against Plasmodium falciparum malaria. Proteins. 50:2003;400-409
9. Daubenberger C.A., Nickel B., Ciatto C., Grutter M.G., Poltl-Frank F., Rossi L., Siegler U., Robinson J., Kashala O., Patarroyo M.E., Pluschke G. Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained. Eur. J. Immunol. 32:2002;3667-3677
10. Fauchere J.L., Thurieau C. Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design. Adv. Drug. Res. 23:1992;127-159
11. Guichard G., Calbo S., Muller S., Kourilsky P., Briand J.P., Abastado J.P. Efficient binding of reduced peptide bond pseudopeptides to major histocompatibility complex class I molecule. J. Biol. Chem. 270:1995;26057-26059
12. Helg A., Mueller M.S., Joss A., Poltl-Frank F., Stuart F., Robinson J.A., Pluschke G. Comparison of analytical methods for the evaluation of antibody responses against epitopes of polymorphic protein antigens. J. Immunol. Methods. 276:2003;19-31
13. Herrera S., Perlaza B.L., Bonelo A., Arevalo-Herrera M. Aotus monkeys: their great value for anti-malaria vaccines and drug testing. Int. J. Parasitol. 32:2002;1625-1635
14. Hill C.M., Liu A., Marshall K.W., Mayer J., Jorgensen B., Yuan B., Cubbon R.M., Nichols E.A., Wicker L.S., Rothbard J.B. Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401. J. Immunol. 152:1994;2890-2898
15. Holder A.A., Blackman M.J. What is the function of MSP-1 on the malaria merozoite? Parasitol. Today. 10:1994;182-184
16. Holder A.A., Guevara Patino J.A., Uthaipibull C., Syed S.E., Ling I.T., Scott-Finnigan T., Blackman M.J. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia. 41:1999;409-414
17. Kashala O., Amador R., Valero M.V., Moreno A., Barbosa A., Nickel B., Daubenberger C.A., Guzman F., Pluschke G., Patarroyo M.E. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine. 20:2002;2263-2277
18. Levitsky V., Zhang Q.J., Levitskaya J., Masucci M.G. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4a. J. Exp. Med. 183:1996;915-926
19. Lioy E., Suarez J., Guzman F., Siegrist S., Pluschke G., Patarroyo M.E. Synthesis, biological, and immunological properties of cyclic peptides from Plasmodium falciparum merozoite surface protein-1. Angew. Chem Int. Ed Engl. 40:2001;2631-2635
20. Lozano J.M., Alba M.P., Vanegas M., Silva Y., Torres-Castellanos J.L., Patarroyo M.E. MSP-1 malaria pseudopeptide analogs: biological and immunological significance and three-dimensional structure. Biol. Chem. 384:2003;71-82
21. Lozano J.M., Espejo F., Diaz D., Salazar L.M., Rodriguez J., Pinzon C., Calvo J.C., Guzman F., Patarroyo M.E. Reduced amide pseudopeptide analogues of a malaria peptide possess secondary structural elements responsible for induction of functional antibodies which react with native proteins expressed in Plasmodium falciparum erythrocyte stages. J. Pept. Res. 52:1998;457-469
22. Lyon J.A., Haynes J.D., Diggs C.L., Chulay J.D., Haidaris C.G., Pratt-Rossiter J. Monoclonal antibody characterization of the 195-kDa major surface glycoprotein of Plasmodium falciparum malaria schizonts and merozoites: identification of additional processed products and a serotype-restricted repetitive epitope. J. Immunol. 138:1987;895-901
23. Moorthy V., Hill A.V. Malaria vaccines. Br. Med. Bull. 62:2002;59-72
24. Moreno R., Jiang L., Moehle K., Zurbriggen R., Gluck R., Robinson J.A., Pluschke G. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochemistry. 2:2001;838-843
25. Ostankovitch M., Guichard G., Connan F., Muller S., Chaboissier A., Hoebeke J., Choppin J., Briand J.P., Guillet J.G. A partially modified retro-inverso pseudopeptide modulates the cytokine profile of CTL specific for an influenza virus epitope. J. Immunol. 161:1998;200-208
26. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:1989;2237-2242
27. Patarroyo M.E., Romero P., Torres M.L., Clavijo P., Moreno A., Martinez A., Rodriguez R., Guzman F., Cabezas E. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature. 328:1987;629-632
28. Pfeiffer B., Peduzzi E., Moehle K., Zurbriggen R., Gluck R., Pluschke G., Robinson J.A. A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew. Chem. Int. Ed Engl. 42:2003;2368-2371
29. Phillips R.S. Current status of malaria and potential for control. Clin. Microbiol. Rev. 14:2001;208-226
30. Rodriguez R., Moreno A., Guzman F., Calvo M., Patarroyo M.E. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 43:1990;339-354
31. Rotzschke O., Falk K., Mack J., Lau J.M., Jung G., Strominger J.L. Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes. Proc. Natl. Acad. Sci. USA. 96:1999;7445-7450
32. Sant'Angelo D.B., Robinson E., Janeway C.A. Jr., Denzin L.K. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor. Eur. J. Immunol. 32:2002;2510-2520
33. Shi Y.P., Hasnain S.E., Sacci J.B., Holloway B.P., Fujioka H., Kumar N., Wohlhueter R., Hoffman S.L., Collins W.E., Lal A.A. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc. Natl. Acad. Sci. USA. 96:1999;1615-1620
34. Stemmer C., Quesnel A., Prevost-Blondel A., Zimmermann C., Muller S., Briand J.P., Pircher H. Protection against lymphocytic choriomeningitis virus infection induced by a reduced peptide bond analogue of the H-2Db-restricted CD8(+) T cell epitope GP33. J. Biol. Chem. 274:1999;5550-5556
35. Stowers A.W., Miller L.H. Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development? Trends Parasitol. 17:2001;415-419
36. Urquiza M., Rodriguez L.E., Suarez J.E., Guzman F., Ocampo M., Curtidor H., Segura C., Trujillo E., Patarroyo M.E. Identification of Plasmodium falciparum MSP-1 peptides able to bind to human red blood cells. Parasite Immunol. 18:1996;515-526
37. Valero M.L., Camarero J.A., Haack T., Mateu M.G., Domingo E., Giralt E., Andreu D. Native-like cyclic peptide models of a viral antigenic site: finding a balance between rigidity and flexibility. J. Mol. Recognit. 13:2000;5-13
38. Van Der Merwe P.A., Davis S.J. Molecular interactions mediating T cell antigen recognition. Annu. Rev. Immunol. 21:2003;659-684
39. Van Regenmortel M.H. Antigenicity and immunogenicity of synthetic peptides. Biologicals. 29:2001;209-213
40. Van Regenmortel M.H., Guichard G., Benkirane N., Briand J.P., Muller S., Brown F. The potential of retro-inverso peptides as synthetic vaccines. Dev. Biol Stand. 92:1998;139-143
41. Van Regenmortel M.H., Muller S. D-peptides as immunogens and diagnostic reagents. Curr. Opin. Biotechnol. 9:1998;377-382
42. Wang J.H., Reinherz E.L. Structural basis of T cell recognition of peptides bound to MHC molecules. Mol. Immunol. 38:2002;1039-1049